EGFR Mutation in Neonatal Nephrocutaneous Syndrome: Unveiling a Genetic Challenge

Abstract

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that exhibits tyrosine kinase signaling activity, playing a pivotal role in various cellular processes. Overexpression or overactivity of EGFR is significantly associated with inflammatory and malignant diseases, particularly lung cancer. Conversely, germline loss-of-function mutations in EGFR have been distinctly linked to a rare condition known as neonatal nephrocutaneous syndrome. We report a case of a preterm female neonate, born to consanguineous parents and from a pregnancy that was complicated by polyhydramnios. From birth, she displayed distinctive clinical features, including fragile skin and widespread erythema, sparse scalp hair, bilateral ankyloblepharon, thick eyebrows, and arachnodactyly. Subsequently, she developed progeroid features marked by skin desquamation, along with failure to thrive, diarrhea, and severe electrolyte and acid–base imbalances. Additional complications comprised anemia, generalized mucocutaneous candidiasis, external otitis, and recurrent septic episodes. Genetic analysis confirmed a homozygous EGFR mutation c.1283G > A p.(Gly428Asp). The infant's neurological status remained stable, albeit requiring pain management through oral morphine and gabapentin. Palliative care became imperative, given the dismal prognosis. The identified mutation is exceedingly rare, with only 24 reported cases known thus far. Each of these instances resulted in a complex multisystemic condition marked by a wide range of challenging symptoms and signs. This clinical journey highlights the intricate interplay among genetic mutations and complex medical conditions, and underscores the critical significance of multidisciplinary care.

Keywords

epidermal growth factor receptor - erythroderma - Romani - preterm - mutation

Authors' Contributions

M.S.L. analyzed and collected data, and wrote the original draft. C.M. wrote the original draft and reviewed the manuscript. A.F., J.R.-S., R.C., J.T., and L.R. reviewed the manuscript.

Publication History

Received: 15 August 2024

Accepted: 25 November 2024

Article published online:
28 December 2024

• References

• 1 Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12 (18) 5268-5272
• 2 Robichaux JP, Elamin YY, Tan Z. et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 2018; 24 (05) 638-646
• 3 Campbell P, Morton PE, Takeichi T. et al. Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol 2014; 134 (10) 2570-2578
• 4 Alruwaithi M, Sherlock M. A210 neonatal inflammatory skin and bowel disease caused by a homozygous EGFR mutation: a case report and review of the medical literature. J Can Assoc Gastroenterol 2018; 1 (Suppl. 01) 367-368
• 5 Mazurova S, Tesarova M, Zeman J. et al. Fatal neonatal nephrocutaneous syndrome in 18 Roma children with EGFR deficiency. J Dermatol 2020; 47 (06) 663-668
• 6 Lemos M, Gonçalves JS, Correia CR. et al. Neonatal inflammatory skin and bowel disease type 2: a very rare disease associated with EGFR mutation. J Pediatr Neonat Individualized Med 2020; 10 (01) e100123
• 7 Ganetzky R, Finn E, Bagchi A. et al. EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features. Mol Genet Genomic Med 2015; 3 (05) 452-458
• 8 Labbouz S, Keegan G, King T. Neonatal cutaneous inflammatory syndrome associated with homozygous epidermal growth factor receptor mutation. Pediatr Dermatol 2023; 40 (01) 171-175
• 9 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 10 Mačeková S, Mathia M, Dojčáková D. Frequency of epidermal growth factor receptor gene variant in Roma population. Genet Test Mol Biomarkers 2023; 27 (11) 357-359
• 11 Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16 (09) 1425-1433
• 12 Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol 2015; 2 (04) e1004969
• 13 Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 2016; 46 (04) 291-298
• 14 Hayashi S, Yokoi T, Hatano C. et al. Biallelic mutations of EGFR in a compound heterozygous state cause ectodermal dysplasia with severe skin defects and gastrointestinal dysfunction. Hum Genome Var 2018; 5: 11
• 15 Asadi P, Samii R, Vahidnezhad F. et al. Abstract #1411492: loss-of-function EGFR mutation in Bartter syndrome with neonatal epithelial autoinflammation. Endocr Pract 2023; 29 (5, suppl): S44